Désémber 2020: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group in desperate need of new and effective treatments.
Papanggihan ieu dibere dina Rapat Taunan 2020 maya Amérika Society of Hematology.
Traditionally, around half of patients with high-risk LBCL, a subgroup of the disease in which patients have double- or triple-hit lymphoma or additional clinical risk factors identified by the International Prognostic Index (IPI), have not achieved long-term disease remission with standard treatment approaches such as chemoimmunotherapy.
This trial represents a step toward making Terapi sél T mobil a first-line treatment option for patients with aggressive B-cell lymphoma,” said Sattva S. Neelapu, M.D., professor of Lymphoma and Myeloma. “At the moment, patients with newly diagnosed aggressive B-cell lymphoma get chemotherapy for about six months. Terapi sél T mobil, if successful, may make it a one-time infusion with treatment completed in one month.
Dumasar kana panilitian konci ZUMA-1, Axi-cel ayeuna dilisensikeun pikeun pengobatan jalma anu kambuh atanapi LBCL refractory anu parantos ngagaduhan dua atanapi langkung jalur perawatan sistemik. Uji coba ZUMA-12 mangrupikeun uji labél kabuka Fase 2, panangan tunggal, percobaan multiséntral anu diwangun dina pamanggihan percobaan ZUMA-1 pikeun meunteun pamakean axi-cel salaku terapi lini kahiji pikeun penderita LBCL anu résiko luhur. .
Numutkeun kana ulikan interim ZUMA-12, 85 persén pasien anu dirawat ku axi-cel ngagaduhan réspon sadayana, sareng 74% ngagaduhan réspon lengkep. Sanggeus median nurutan-up 9.3 bulan, 70% tina penderita direkrut exhibited respon neraskeun di cutoff data.
White blood cell count reduction, encephalopathy, anaemia, and sindrom sékrési sitokin were the most common side effects linked with axi-cel treatment. By the time the data was analysed, all adverse events had been resolved.
Furthermore, when compared to when the immunotherapy products were generated from patients who had already received several lines of chemotherapy, the peak level of CAR T cells present in the blood, as well as the median CAR T cell expansion, were higher in this trial of first-line Terapi sél T mobil.
"Kabugaran sél T ieu tiasa dikaitkeun kana éféktivitas terapi anu langkung ageung, nyababkeun hasil pasien anu langkung saé," tambah Neelapu.
Saatos hasil interim anu saé ZUMA-12, panalungtik ngarencanakeun pikeun neraskeun nuturkeun pasien pikeun mastikeun yén réaksina kana pangobatan tahan panjang.
“A randomised clinical trial would be required to definitely demonstrate that CAR T cell therapy is superior to existing standard of care with chemoimmunotherapy in these high-risk patients if the responses are persistent after prolonged follow-up,” Neelapu said. It also begs the question of whether CAR T cell treatment should be tested in intermediate-risk patients with big sél B limfoma.
